Melbourne, Australia, 25 September 2017: Sienna Cancer Diagnostics, a commercial stage, medical technology company focused on the development and commercialisation of innovative cancer-related tests, is delighted to announce the appointment of Axlab A/S as its exclusive distribution partner for Denmark and Sweden.
This is the first distribution agreement to be signed since Sienna’s ASX listing and will broaden and accelerate the global roll out of its in-vitro diagnostic (IVD) test. The agreement provides Axlab with the right to sell Sienna’s product to pathology laboratories where it will be used as an adjunct to urine cytology to assist pathologists and urologists in their diagnosis of bladder cancer.
For further information please download PDF attached:
Download this document